Tony Hunter | |
|---|---|
 Anthony Rex Hunter | |
| Born | Anthony Rex Hunter 23 August 1943 United Kingdom |
| Nationality | British |
| Alma mater | |
| Known for | Kinases[5] |
| Awards |
|
| Scientific career | |
| Fields | Biology |
| Institutions | |
| Thesis | Aspects of mammalian protein synthesis (1969) |
| Doctoral advisor | Asher Korner[1] |
| Notable students | Jonathon Pines (postdoc)[2][3][4] |
| Website | www |
Anthony Rex Hunter (born 23 August 1943) is a British-American biologist who is a professor of biology at the Salk Institute for Biological Studies and the University of California San Diego. His research publications list his name as Tony Hunter.[6]
YouTube Encyclopedic
-
1/5Views:5 912639604499606
-
Tony Hunter - Salk Institute Lecture of the Month Series
-
Tony Hunter: Remembering Jonas Salk
-
The Role of the LIF Stem Cell Factor in Pancreatic Cancer - Tony Hunter, Salk Institute
-
Conquering Cancer Initiative Summit 2019: Program with Ronald Evans, Dannielle Engle and Tony Hunter
-
Interview with Tony Hunter
Transcription
Early life and education
Hunter was born in 1943 in the United Kingdom and educated at Felsted School, prior to Christ's College, Cambridge, where he was awarded a PhD in 1969 for research on protein synthesis.[7]
Career and research
Following his PhD, Hunter held a fellowship at Christ's College, Cambridge, in Cambridge (1968–1971) and (1973–1975). From 1971 to 1973, he was a postdoctoral research associate of the Salk Institute for Biological Studies in La Jolla, California. He was then assistant professor 1975–78, associate professor 1978–82, professor 1982 onwards and since 2008 director of the Salk Institute Cancer Center.[8] He also sits on the Selection Committee for Life Science and Medicine which chooses winners of the Shaw Prize.
Hunter is one of the foremost recognized leaders in the field of cell growth control, growth factor receptors and their signal transduction pathways. He is well known for discovering that tyrosine phosphorylation is a fundamental mechanism for transmembrane-signal transduction in response to growth factor stimulation and that disregulation of such tyrosine phosphorylation, by activated oncogenic protein tyrosine kinases,[5] is a pivotal mechanism utilized in the malignant transformation of cells. His work is important in signaling pathways and their disorders.
Hunter was a founder of Signal Pharmaceuticals.[citation needed]
Awards and honors
He won the Wolf Prize in Medicine in 2005 for "the discovery of protein kinases that phosphorylate tyrosine residues in proteins, critical for the regulation of a wide variety of cellular events, including malignant transformation".[9] He has been granted along with Charles Sawyers and Joseph Schlessinger with the 2014 BBVA Foundation Frontiers of Knowledge Award in the Biomedicine category for "carving out the path that led to the development of a new class of successful cancer drugs".
- 1987 Fellow of the Royal Society (FRS)[10]
- 1994 Charles S. Mott Prize by the General Motors Cancer Research Foundation.
- 1994 Gairdner Foundation International Award.
- 1998 Member of the US National Academy of Sciences.[11]
- 2001 Keio Medical Science Prize[12]
- 2004 Louisa Gross Horwitz Prize from Columbia University.[13]
- 2005 Wolf Prize in Medicine
- 2006 Pasarow Award in Cancer Research.[14]
- 2014 Royal Medal
- 2014 BBVA Foundation Frontiers of Knowledge Award in Biomedicine
- 2017 Sjöberg Prize for Cancer Research[15]
- 2018 Tang Prize
- 2018 Pezcoller Foundation-AACR International Award for Cancer Research[16]
References
- ^ "Tony Hunter Lab". Archived from the original on 13 October 2016. Retrieved 21 December 2016.
- ^ Pines, Jonathon; Hunter, Tony (1990). "Human cyclin A is adenovirus E1A-associated protein p60 and behaves differently from cyclin B". Nature. 346 (6286): 760–763. Bibcode:1990Natur.346..760P. doi:10.1038/346760a0. PMID 2143810. S2CID 4333058.
- ^ Hunter, Tony; Pines, Jonathon (1991). "Cyclins and cancer". Cell. 66 (6): 1071–1074. doi:10.1016/0092-8674(91)90028-W. PMID 1833062. S2CID 29568380.
- ^ Hunter, Tony; Pines, Jonathan (1994). "Cyclins and cancer II: Cyclin D and CDK inhibitors come of age". Cell. 79 (4): 573–582. doi:10.1016/0092-8674(94)90543-6. PMID 7954824. S2CID 24867886.
- ^ a b Hunter, Tony (May 2008). "Tony Hunter: kinase king. Interview by Ruth Williams". J. Cell Biol. 181 (4): 572–3. doi:10.1083/jcb.1814pi. PMC 2386096. PMID 18490508.
- ^ Bailis, J. M.; Luche, D. D.; Hunter, T.; Forsburg, S. L. (2008). "Minichromosome Maintenance Proteins Interact with Checkpoint and Recombination Proteins to Promote S-Phase Genome Stability". Molecular and Cellular Biology. 28 (5): 1724–1738. doi:10.1128/MCB.01717-07. PMC 2258774. PMID 18180284.
- ^ Hunter, Anthony Rex (1969). Aspects of mammalian protein synthesis (PhD thesis). University of Cambridge. OCLC 500479081.
- ^ "Tony Hunter FRS". Debretts. Retrieved 18 July 2010.
- ^ "The Wolf Prize in Medicine". Archived from the original on 26 February 2009. Retrieved 29 April 2010.
{{cite web}}: CS1 maint: bot: original URL status unknown (link). wolffund.org.il - ^ "Lists of Royal Society Fellows 1660–2007". London: Royal Society. Archived from the original on 24 March 2010. Retrieved 18 July 2010.
- ^ National Academy of Science Member Directory. Retrieved on 2017-12-08.
- ^ The Keio Medical Science Prize Archived 3 March 2016 at the Wayback Machine. Ms-fund.keio.ac.jp. Retrieved on 2013-10-08.
- ^ Tony Hunter at The Salk Institute. Biology.ucsd.edu. Retrieved on 2013-10-08.
- ^ Tony Hunter Receives Pasarow Award for Cancer Research. Salk Institute for Biological Studies (2011)
- ^ Salk scientist awarded inaugural Sjöberg Prize for cancer breakthrough. Salk.edu. Retrieved on 2017-03-02.
- ^ "THE PEZCOLLER FOUNDATION-AACR INTERNATIONAL AWARD". Pezcoller Foundation. Retrieved 6 November 2019.
| International | |
|---|---|
| National | |
| Academics | |
| Other | |
This page was last edited on 28 December 2023, at 07:13